Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Vision therapy

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44338   clinical trials with a EudraCT protocol, of which   7368   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    195 result(s) found for: Vision therapy. Displaying page 1 of 10.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2010-021662-30 Sponsor Protocol Number: CRFB002F2301 Start Date*: 2010-11-05
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A 12 month, phase III, randomized, double-masked, multi-center, active-controlled study to evaluate the efficacy and safety of two different dosing regimens of 0.5 mg ranibizumab vs. verteporfin PD...
    Medical condition: visual impairment due to choroidal neovascularization secondary to pathologic myopia
    Disease: Version SOC Term Classification Code Term Level
    12.1 10036803 Progressive high (degenerative) myopia LLT
    12.1 10060837 Choroidal neovascularization LLT
    12.1 10047571 Visual impairment LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PT (Completed) LV (Completed) HU (Completed) LT (Completed) FR (Completed) ES (Completed) IT (Completed) AT (Completed) SK (Completed) DE (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2005-001539-31 Sponsor Protocol Number: FE999905 CS002 Start Date*: 2005-09-16
    Sponsor Name:Ferring Pharmaceuticals A/S
    Full Title: An Open-label, Multi-centre, Phase III Study of Local Tolerability of Zomacton 10 mg (Recombinant Somatropin) administered by ZomaJet Vision X
    Medical condition: Zomacton is indicated for the long term treatment of children who have growth failure due to inadequate secretion of growth hormone and for the long-term treatment of growth retardation due to Turn...
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: CZ (Completed)
    Trial results: View results
    EudraCT Number: 2011-001520-37 Sponsor Protocol Number: KETECT Start Date*: 2014-02-14
    Sponsor Name:Skåne University Hospital, Malmö
    Full Title: Ketamine as an alternative to electroconvulsive therapy for treatment of major depressive disorder
    Medical condition: Major depression disorder
    Disease: Version SOC Term Classification Code Term Level
    18.0 10037175 - Psychiatric disorders 10019063 Hallucination PT
    18.0 10015919 - Eye disorders 10013036 Diplopia PT
    18.0 100000004863 10061243 Post procedural nausea LLT
    18.0 10029205 - Nervous system disorders 10047343 Vertigo CNS origin PT
    18.0 10037175 - Psychiatric disorders 10015533 Euphoria LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-000280-23 Sponsor Protocol Number: BISS Start Date*: 2020-08-20
    Sponsor Name:Prof Mathias Abegg
    Full Title: A pragmatic, randomized, non-inferiority trial comparing the effectiveness of Botulinum toxin-based treatment with conventional strabismus surgery in acquired esotropia
    Medical condition: Acquired esotropia (strabismus)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004853 10015475 Esotropia LLT
    20.0 100000004853 10042163 Strabismus NOS LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2021-000183-29 Sponsor Protocol Number: REVISION Start Date*: 2022-03-09
    Sponsor Name:Eberhard-Karls University Tübingen, Med. Fac. rep. by University Hospital and its Commercial Director
    Full Title: Early Reperfusion Therapy with Intravenous Alteplase for Recovery of VISION in Acute Central Retinal Artery Occlusion (REVISION) - A double-blind randomized placebo-controlled phase III proof-of-co...
    Medical condition: Acute non-arteritic central retinal artery occlusion (CRAO)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10015919 - Eye disorders 10007971 Central retinal artery occlusion LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2012-001006-24 Sponsor Protocol Number: RAVIT-DME_7.12.2011 Start Date*: 2013-08-23
    Sponsor Name: [...]
    1.
    2. Augenklinik Universitaetsallee
    Full Title: Ranibizumab and Vitrectomy in the Therapy of Diabetic Macular Edema (The RAVIT-DME-Trial)
    Medical condition: therapy of diabetic macular edema
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2020-002255-37 Sponsor Protocol Number: MGT-RPGR-022 Start Date*: 2022-05-26
    Sponsor Name:MeiraGTx UK II Limited
    Full Title: Phase 3 Follow-up Study of AAV5-hRKp.RPGR for the Treatment of X-linked Retinitis Pigmentosa Associated with Variants in the RPGR gene
    Medical condition: X-Linked Retinitis Pigmentosa caused by mutations in the RPGR gene
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10038914 Retinitis pigmentosa PT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: IE (Prematurely Ended) NL (Trial now transitioned) BE (Trial now transitioned) ES (Ongoing) FR (Trial now transitioned) DK (Trial now transitioned) DE (Prematurely Ended) IT (Trial now transitioned) Outside EU/EEA
    Trial results: (No results available)
    EudraCT Number: 2020-002873-88 Sponsor Protocol Number: MGT-RPGR-021 Start Date*: 2022-07-19
    Sponsor Name:MeiraGTx UK II Limited
    Full Title: Phase 3 Randomized, Controlled Study of AAV5-hRKp.RPGR for the Treatment of X-linked Retinitis Pigmentosa Associated with Variants in the RPGR gene
    Medical condition: X-Linked Retinitis Pigmentosa caused by mutations in the RPGR gene
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10038914 Retinitis pigmentosa PT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: IE (Completed) NL (Ongoing) BE (Completed) ES (Ongoing) FR (Completed) DK (Completed) DE (Prematurely Ended) IT (Completed) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2011-003475-11 Sponsor Protocol Number: UCL/11/0083 Start Date*: 2011-11-15
    Sponsor Name:University College London (UCL)
    Full Title: A phase II double-blind, randomised, placebo-controlled trial of neuroprotection with phenytoin in acute optic neuritis
    Medical condition: Acute demyelinating optic neuritis
    Disease: Version SOC Term Classification Code Term Level
    16.0 10029205 - Nervous system disorders 10030942 Optic neuritis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2008-008135-28 Sponsor Protocol Number: 01-281108 Start Date*: 2009-04-16
    Sponsor Name:Hull and East Yorkshire NHS Hospitals Trust
    Full Title: Effect of Sildenafil on Pulmonary Artery Pressure during hypoxia and exercise in Chronic Heart Failure
    Medical condition: We will investigate the effect of sildenafil on pulmonary artery pressure in Heart failure patients (impaired heart function). Patients will be recruited from the Heart Failure clinic at Castle Hil...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10002034 Anaemia LLT
    9.1 10040756 Sinusitis NOS LLT
    9.1 10016807 Fluid retention LLT
    9.1 10022437 Insomnia LLT
    9.1 10016998 Forehead headache LLT
    9.1 10010108 Common migraine LLT
    9.1 10002855 Anxiety LLT
    9.1 10044565 Tremor LLT
    9.1 10033987 Paresthesia LLT
    9.1 10006790 Burning sensation NOS LLT
    9.1 10020937 Hypoaesthesia LLT
    9.1 10007882 Cellulitis LLT
    9.1 10022000 Influenza LLT
    9.1 10038870 Retinal hemorrhage LLT
    9.1 10047544 Visual disturbance NOS LLT
    9.1 10047513 Vision blurred LLT
    9.1 10034960 Photophobia LLT
    9.1 10008795 Chromatopsia LLT
    9.1 10051819 Cyanopsia LLT
    9.1 10015910 Eye blood shot LLT
    9.1 10015946 Eye irritation LLT
    9.1 10038189 Red eye LLT
    9.1 10047531 Visual acuity reduced LLT
    9.1 10013036 Diplopia LLT
    9.1 10000173 Abnormal sensation in eye LLT
    9.1 10047340 Vertigo LLT
    9.1 10065027 Sudden deafness LLT
    9.1 10016825 Flushing LLT
    9.1 10006461 Bronchitis NOS LLT
    9.1 10015090 Epistaxis LLT
    9.1 10039092 Rhinitis NOS LLT
    9.1 10011224 Cough LLT
    9.1 10028735 Nasal congestion LLT
    9.1 10012735 Diarrhoea LLT
    9.1 10013946 Dyspepsia LLT
    9.1 10017869 Gastritis NOS LLT
    9.1 10017888 Gastroenteritis LLT
    9.1 10017885 Gastrooesophageal reflux disease LLT
    9.1 10019022 Haemorrhoids LLT
    9.1 10000060 Abdominal distension LLT
    9.1 10013781 Dry mouth LLT
    9.1 10001760 Alopecia LLT
    9.1 10015150 Erythema LLT
    9.1 10029410 Night sweats LLT
    9.1 10040913 Skin rash LLT
    9.1 10028411 Myalgia LLT
    9.1 10003988 Back pain LLT
    9.1 10018800 Gynaecomastia LLT
    9.1 10036661 Priapism LLT
    9.1 10052791 Erection increased (excl priapism) LLT
    9.1 10037660 Pyrexia LLT
    9.1 10042438 Sudden hearing loss, unspecified LLT
    9.1 10033425 Pain in extremity LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2004-001453-28 Sponsor Protocol Number: CRFB002B2201 Start Date*: 2004-11-19
    Sponsor Name:Novartis Pharma AG
    Full Title: Open-label, Multicenter, Phase II Study Assessing the Safety of Lucentis (ranibizumab) Administered in Conjunction with Photodynamic Therapy with Visudyne in Patients with Occult or Predominantly C...
    Medical condition: Male and female patients > 50 years of age with subfoveal choroidal neovascularization (CNV) secondary to AMD.
    Disease: Version SOC Term Classification Code Term Level
    7.0 10060837 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2005-005592-14 Sponsor Protocol Number: 26 Start Date*: 2006-07-27
    Sponsor Name:IFSgGmbH, Institute for clinical research
    Full Title: Double blind, placebo-controlled study to determine the safety and efficacy of erythropoietin as an add-on therapy to methylprednisolone in subjects with acute autoimmune optic neuritis (VISION PRO...
    Medical condition: Multiple sclerosis (MS) is a chronic disease of the central nervous system.Optic neuritis represents one of the most common and frequently the first clinical manifestation of MS. Optic neuritis is ...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2006-001386-42 Sponsor Protocol Number: REC no:06/Q0403/25 Start Date*: 2006-07-06
    Sponsor Name:Imperial College
    Full Title: The timing of intra-vitreal (4mg) triamcinolone acetonide, in addition to verteporfin photodynamic therapy for choroidal neovascularisation, in age-related macular degeneration: a prospective rando...
    Medical condition: Submacular choroidal neovascularisation in Age-related Macular Degeneration
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2014-002381-73 Sponsor Protocol Number: PATP1023 Start Date*: 2014-10-02
    Sponsor Name:Moorfields Eye Hospital
    Full Title: Individualizing therapy for neovascular age-related macular degeneration with aflibercept
    Medical condition: Neovascular age-related macular degeneration
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2015-001266-26 Sponsor Protocol Number: GS-LHON-CLIN-03B Start Date*: 2016-01-21
    Sponsor Name:GENSIGHT-BIOLOGICS
    Full Title: A Randomized, Double-Masked, Sham-Controlled, Pivotal Clinical Trial to Evaluate the Efficacy of a Single Intravitreal Injection of GS010 (rAAV2/2-ND4) in Subjects Affected for more than 6 months a...
    Medical condition: Leber Hereditary Optic Neuropathy due to mutations in the mitochondrial NADH Dehydrogenase 4 gene
    Disease:
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2017-004825-34 Sponsor Protocol Number: KHB-1801 Start Date*: 2019-01-14
    Sponsor Name:Chengdu Kanghong Biotechnology Co., Ltd.
    Full Title: A Multicenter, Double-Masked, Randomized, Dose-Ranging Trial to Evaluate the Efficacy and Safety of Conbercept Intravitreal Injection in Subjects with Neovascular Age related Macular Degeneration
    Medical condition: Neovascular Age Related Macular Degeneration
    Disease: Version SOC Term Classification Code Term Level
    20.1 10015919 - Eye disorders 10064930 Age-related macular degeneration PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) NL (Completed) LT (Prematurely Ended) AT (Completed) BE (Completed) ES (Prematurely Ended) PT (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2015-001383-18 Sponsor Protocol Number: Start Date*: 2015-11-30
    Sponsor Name:University of Oxford
    Full Title: An open label Phase 2 clinical trial of retinal gene therapy for choroideremia using an adeno-associated viral vector (AAV2) encoding Rab-escort protein 1 (REP1)
    Medical condition: Choroideremia - a currently incurable retinal degeneration caused by null mutations in the CHM gene encoding REP1 protein located on the X chromosome. The condition causes blindness in males by the...
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004853 10008791 Choroideremia LLT
    Population Age: Adults Gender: Male
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2015-001265-11 Sponsor Protocol Number: GS-LHON-CLIN-03A Start Date*: 2016-01-21
    Sponsor Name:GENSIGHT-BIOLOGICS
    Full Title: A Randomized, Double-Masked, Sham-Controlled, Pivotal Clinical Trial to Evaluate the Efficacy of a Single Intravitreal Injection of GS010 (rAAV2/2-ND4) in Subjects Affected for 6 Months or Less by...
    Medical condition: Leber Hereditary Optic Neuropathy due to mutations in the mitochondrial NADH Dehydrogenase 4 gene
    Disease:
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2017-004826-14 Sponsor Protocol Number: KHB-1802 Start Date*: 2019-01-09
    Sponsor Name:Chengdu Kanghong Biotechnology Co., Ltd.
    Full Title: A Multicenter, Double-Masked, Randomized, Dose-Ranging Trial to Evaluate the Efficacy and Safety of Conbercept Intravitreal Injection in Subjects with Neovascular Age related Macular Degeneration
    Medical condition: Neovascular Age Related Macular Degeneration
    Disease: Version SOC Term Classification Code Term Level
    20.1 10015919 - Eye disorders 10064930 Age-related macular degeneration PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) LV (Completed) CZ (Completed) SK (Prematurely Ended) DK (Prematurely Ended) BG (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-000130-18 Sponsor Protocol Number: 1 Start Date*: 2020-10-09
    Sponsor Name:Fundación para la Inv. Biomédica Hospital Clínico San Carlos
    Full Title: Co-THEIA (Combination THerapy with mEthotrexate and adalImumAb for uveitis): Efficacy, safety and cost-effectiveness of methotrexate, adalimumab, or their combination in non infectious non anterior...
    Medical condition: Non infectious non anterior uveitis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 24 06:55:57 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA